BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Broder MS, Beenhouwer D, Strosberg JR, Neary MP, Cherepanov D. Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: A systematic literature review. World J Gastroenterol 2015; 21(6): 1945-1955 [PMID: 25684964 DOI: 10.3748/wjg.v21.i6.1945]
URL: https://www.wjgnet.com/1007-9327/full/v21/i6/1945.htm
Number Citing Articles
1
Tetsuhide Ito, Lingaku Lee, Robert T. Jensen. Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversiesExpert Opinion on Pharmacotherapy 2016; 17(16): 2191 doi: 10.1080/14656566.2016.1236916
2
Georgios K Dimitriadis, Martin O Weickert, Harpal S Randeva, Gregory Kaltsas, Ashley Grossman. Medical management of secretory syndromes related to gastroenteropancreatic neuroendocrine tumoursEndocrine-Related Cancer 2016; 23(9): R423 doi: 10.1530/ERC-16-0200
3
Burcin Özdirik, Frank Tacke, Fabian Benz, Holger Amthauer, Uli Fehrenbach, Christoph Roderburg, Henning Jann. A case report of an excellent response to interferon- α in a patient with functional metastasized neuroendocrine tumor refractory to other treatmentsMedicine 2020; 99(25): e20820 doi: 10.1097/MD.0000000000020820
4
Francesco Panzuto, Maria Rinzivillo. Neuroendocrine Neoplasia Management2021; : 201 doi: 10.1007/978-3-030-72830-4_15
5
Fang Yu, Tingting Zhang, Fenghua Fu, Aiping Wang, Xinyong Liu. Preparation of Long-Acting Somatostatin and GnRH Analogues and Their Applications in Tumor TherapyCurrent Drug Delivery 2022; 19(1): 5 doi: 10.2174/1567201819666211224113311
6
I. A. Ilovayskaya. Octreotide in the treatment of acromegaly – the possibilities of high-dose therapyMeditsinskiy sovet = Medical Council 2022; (10): 148 doi: 10.21518/2079-701X-2022-16-10-148-152
7
Chan Shen, Ying Xu, Arvind Dasari, Ya-Chen Tina Shih, James C. Yao. Octreotide LAR Dosage and Survival Among Elderly Patients With Distant-Stage Neuroendocrine TumorsThe Oncologist 2016; 21(3): 308 doi: 10.1634/theoncologist.2015-0381
8
Angela Lamarca, Jorge Barriuso, Mairéad G McNamara, Richard A Hubner, Juan W Valle. Telotristat ethyl: a new option for the management of carcinoid syndromeExpert Opinion on Pharmacotherapy 2016; 17(18): 2487 doi: 10.1080/14656566.2016.1254191
9
A. Faggiano, F. Lo Calzo, G. Pizza, R. Modica, A. Colao. The safety of available treatments options for neuroendocrine tumorsExpert Opinion on Drug Safety 2017; 16(10): 1149 doi: 10.1080/14740338.2017.1354984
10
Andreas F. B. Räder, Michael Weinmüller, Florian Reichart, Adi Schumacher-Klinger, Shira Merzbach, Chaim Gilon, Amnon Hoffman, Horst Kessler. Orally Active Peptides: Is There a Magic Bullet?Angewandte Chemie International Edition 2018; 57(44): 14414 doi: 10.1002/anie.201807298
11
Johannes Hofland, Aura D Herrera-Martínez, Wouter T Zandee, Wouter W de Herder. Management of carcinoid syndrome: a systematic review and meta-analysisEndocrine-Related Cancer 2019; 26(3): R145 doi: 10.1530/ERC-18-0495
12
Sally C. Lau, Omar Abdel-Rahman, Winson Y. Cheung. Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumorsMedical Oncology 2018; 35(9) doi: 10.1007/s12032-018-1189-1
13
Thomas Y. Wong, Kevin S. Zhang, Ripal T. Gandhi, Zachary S. Collins, Ryan O’Hara, Eric A. Wang, Kirubahara Vaheesan, Lea Matsuoka, Daniel Y. Sze, Andrew S. Kennedy, Daniel B. Brown. Long-term outcomes following 90Y Radioembolization of neuroendocrine liver metastases: evaluation of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registryBMC Cancer 2022; 22(1) doi: 10.1186/s12885-022-09302-z
14
Mohammed Dawod, Teresa Alonso Gordoa, Mauro Cives, Louis De Mestier, Joakim Crona, Francesca Spada, Kjel Oberg, Marianne Pavel, Angela Lamarca. Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine TumoursCurrent Treatment Options in Oncology 2021; 22(8) doi: 10.1007/s11864-021-00863-y
15
Venkata K. Pokuri, Mei Ka Fong, Renuka Iyer. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine TumorsCurrent Oncology Reports 2016; 18(1) doi: 10.1007/s11912-015-0492-7
16
Elettra Merola, Francesco Panzuto, Gianfranco Delle Fave. Antiproliferative effect of somatostatin analogs in advanced gastro-entero-pancreatic neuroendocrine tumors: a systematic review and meta-analysisOncotarget 2017; 8(28): 46624 doi: 10.18632/oncotarget.16686
17
Giandomenico Roviello, Laura Zanotti, Sergio Venturini, Alberto Bottini, Daniele Generali. Role of targeted agents in neuroendocrine tumors: Results from a meta-analysisCancer Biology & Therapy 2016; 17(9): 883 doi: 10.1080/15384047.2016.1210735
18
Ludovica Magi, Maria Rinzivillo, Francesco Panzuto. What Gastroenterologists Should Know about Carcinoid SyndromeGastroenterology Insights 2022; 13(1): 127 doi: 10.3390/gastroent13010014
19
Fernando J. Ferrer‐Gago, Li Quan Koh. Methods and Approaches for the Solid‐Phase Synthesis of Peptide AlcoholsChemPlusChem 2020; 85(4): 641 doi: 10.1002/cplu.201900749
20
Andreas F. B. Räder, Michael Weinmüller, Florian Reichart, Adi Schumacher-Klinger, Shira Merzbach, Chaim Gilon, Amnon Hoffman, Horst Kessler. Oral aktive Peptide: Gibt es ein Patentrezept?Angewandte Chemie 2018; 130(44): 14614 doi: 10.1002/ange.201807298
21
Sara Massironi, Dario Conte, Roberta Elisa Rossi. Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedulesScandinavian Journal of Gastroenterology 2016; 51(5): 513 doi: 10.3109/00365521.2015.1115117
22
Pamela Ryan, Alexandria Phan, Daphne Adelman, Michiko Iwasaki. Neuroendocrine Tumors and Lanreotide Depot: Clinical Considerations and Nurse and Patient PreferencesClinical Journal of Oncology Nursing 2016; 20(6): E139 doi: 10.1188/16.CJON.E139-E146
23
А.  М. Тyshchenko, R. M. Smachylo, E.  V. Mushenko, O. V. Ivanenko. Carcinoid of small intestine - the cause of gastro-intestinal hemorrhage and acute ileusKlinicheskaia khirurgiia 2021; 88(5-6): 94 doi: 10.26779/2522-1396.2021.5-6.94
24
Antongiulio Faggiano, Anna Chiara Carratù, Elia Guadagno, Salvatore Tafuto, Fabiana Tatangelo, Ferdinando Riccardi, Carmela Mocerino, Giovannella Palmieri, Vincenzo Damiano, Roberta Siciliano, Silvana Leo, Annamaria Mauro, Lucia Franca Tozzi, Claudia Battista, Gaetano De Rosa, Annamaria Colao. Somatostatin Analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real lifeOncotarget 2016; 7(5): 5538 doi: 10.18632/oncotarget.6686
25
Lynn Huynh, Todor Totev, Francis Vekeman, Maureen P. Neary, Mei S. Duh, Al B. Benson. Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LARJournal of Medical Economics 2017; 20(9): 945 doi: 10.1080/13696998.2017.1337019
26
David L. Chan, Diego Ferone, Manuela Albertelli, Nick Pavlakis, Eva Segelov, Simron Singh. Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic reviewEndocrine 2017; 57(3): 366 doi: 10.1007/s12020-017-1360-z
27
Rachel P. Riechelmann, Allan A. Pereira, Juliana F. M. Rego, Frederico P. Costa. Refractory carcinoid syndrome: a review of treatment optionsTherapeutic Advances in Medical Oncology 2017; 9(2): 127 doi: 10.1177/1758834016675803
28
Francesca Spada, Roberta E. Rossi, Elda Kara, Alice Laffi, Sara Massironi, Manila Rubino, Franco Grimaldi, Sherrie Bhoori, Nicola Fazio. Carcinoid Syndrome and Hyperinsulinemic Hypoglycemia Associated with Neuroendocrine Neoplasms: A Critical Review on Clinical and Pharmacological ManagementPharmaceuticals 2021; 14(6): 539 doi: 10.3390/ph14060539
29
Amir Mehrvarz Sarshekeh, Daniel M Halperin, Arvind Dasari. Update on management of midgut neuroendocrine tumorsInternational Journal of Endocrine Oncology 2016; 3(2): 175 doi: 10.2217/ije-2015-0004
30
Luohai Chen, Nuerailaguli Jumai, Qiao He, Man Liu, Yuan Lin, Yanji Luo, Yu Wang, Min-hu Chen, Zhirong Zeng, Xiangsong Zhang, Ning Zhang. The role of quantitative tumor burden based on [68 Ga]Ga-DOTA-NOC PET/CT in well-differentiated neuroendocrine tumors: beyond prognosisEuropean Journal of Nuclear Medicine and Molecular Imaging 2023; 50(2): 525 doi: 10.1007/s00259-022-05971-x
31
Christoph J Auernhammer, Christine Spitzweg, Martin K Angele, Stefan Boeck, Ashley Grossman, Svenja Nölting, Harun Ilhan, Thomas Knösel, Julia Mayerle, Martin Reincke, Peter Bartenstein. Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategiesThe Lancet Diabetes & Endocrinology 2018; 6(5): 404 doi: 10.1016/S2213-8587(17)30401-1
32
Jorge Enrique Machado-Alba, Manuel Enrique Machado-Duque. Prescription patterns of long-acting somatostatin analoguesSAGE Open Medicine 2017; 5: 205031211769479 doi: 10.1177/2050312117694795
33
Colin Bacorn, Esther Kim, Alexander D Borowsky, Lily Koo Lin. Previously undiagnosed neuroendocrine tumour mimicking breast cancer metastasis to the orbitBMJ Case Reports 2020; 13(5): e234629 doi: 10.1136/bcr-2020-234629
34
Yuhong Wang, Wei Wang, Kaizhou Jin, Cheng Fang, Yuan Lin, Ling Xue, Shiting Feng, Zhiwei Zhou, Chenghao Shao, Minhu Chen, Xianjun Yu, Jie Chen. Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumorsOncology Letters 2017; 13(3): 1165 doi: 10.3892/ol.2017.5591
35
M. Pavel, K. Öberg, M. Falconi, E.P. Krenning, A. Sundin, A. Perren, A. Berruti. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology 2020; 31(7): 844 doi: 10.1016/j.annonc.2020.03.304
36
M. Albertelli, E. Nazzari, S. Sciallero, F. Grillo, S. Morbelli, F. De Cian, G. Cittadini, E. Ambrosetti, A. Ciarmiello, D. Ferone. Anti-tumoral effects of somatostatin analogs: a lesson from the CLARINET studyJournal of Endocrinological Investigation 2017; 40(11): 1265 doi: 10.1007/s40618-017-0692-0
37
Anjie Yang, Jocelyn Brown, Ernie Mak. Persistent Diarrhea after Celiac Plexus Block in a Pancreatic Cancer Patient: Case Report and Literature ReviewJournal of Palliative Medicine 2016; 19(1): 83 doi: 10.1089/jpm.2015.0117
38
Chandrikha Chandrasekharan. Medical Management of Gastroenteropancreatic Neuroendocrine TumorsSurgical Oncology Clinics of North America 2020; 29(2): 293 doi: 10.1016/j.soc.2019.11.004
39
Amanda Kristiansson, Anders Örbom, Oskar Vilhelmsson Timmermand, Jonas Ahlstedt, Sven-Erik Strand, Bo Åkerström. Kidney Protection with the Radical Scavenger α1-Microglobulin (A1M) during Peptide Receptor Radionuclide and Radioligand TherapyAntioxidants 2021; 10(8): 1271 doi: 10.3390/antiox10081271
40
Stephanie M Barrows, Beilei Cai, Catherine Copley-Merriman, Kelly R Wright, Colleen V Castro, Raoudha Soufi-Mahjoubi. Systematic literature review of the antitumor effect of octreotide in neuroendocrine tumorsWorld Journal of Meta-Analysis 2018; 6(2): 9-20 doi: 10.13105/wjma.v6.i2.9
41
Biagio Cangiano, Letizia Maria Fatti, Luca Persani, Giovanni Vitale. Nuovi farmaci a bersaglio molecolare nei tumori neuroendocrini gastroenteropancreaticiL'Endocrinologo 2017; 18(6): 280 doi: 10.1007/s40619-017-0359-2
42
George A. Fisher. Textbook of Gastrointestinal Oncology2019; : 269 doi: 10.1007/978-3-030-18890-0_16
43
Nagarjun Subash, Mishel Maria Papali, Khatri Prashant Bahadur, Chaithanya Avanthika, Sharan Jhaveri, Srijani Thannir, Meet Joshi, Sai Sudha Valisekka. Recent Advances in the Diagnosis and Management of Carcinoid SyndromeDisease-a-Month 2022; 68(7): 101304 doi: 10.1016/j.disamonth.2021.101304
44
Fernando J. Ferrer‐Gago, Li Quan Koh, David P. Lane. Functionalized Resins for the Synthesis of Peptide AlcoholsChemistry – A European Journal 2020; 26(2): 379 doi: 10.1002/chem.201903965
45
David Cella, Jennifer L. Beaumont, Stacie Hudgens, Florence Marteau, Marion Feuilly, Aude Houchard, Pablo Lapuerta, John Ramage, Marianne Pavel, Dieter Hörsch, Matthew H. Kulke. Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTARClinical Therapeutics 2018; 40(12): 2006 doi: 10.1016/j.clinthera.2018.10.008
46
ME Pavel, C Becerra, K Grosch, W Cheung, J Hasskarl, JC Yao. Effect of everolimus on the pharmacokinetics of octreotide long-acting repeatable in patients with advanced neuroendocrine tumors: An analysis of the randomized phase III RADIANT-2 trialClinical Pharmacology & Therapeutics 2017; 101(4): 462 doi: 10.1002/cpt.559
47
Sathish Kumar Mungamuri, Anil Kumar Pasupulati, Vijay Aditya Mavuduru. Exploring Pancreatic Metabolism and Malignancy2019; : 215 doi: 10.1007/978-981-32-9393-9_13
48
Sara Pusceddu, Natalie Prinzi, Alessandra Raimondi, Francesca Corti, Roberto Buzzoni, Maria Di Bartolomeo, Ettore Seregni, Marco Maccauro, Jorgelina Coppa, Massimo Milione, Vincenzo Mazzaferro, Filippo de Braud. Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledgeTumori Journal 2019; 105(2): 113 doi: 10.1177/0300891618765362
49
Anja Rinke, Christoph J Auernhammer, Lisa Bodei, Mark Kidd, Sebastian Krug, Rita Lawlor, Ilaria Marinoni, Aurel Perren, Aldo Scarpa, Halfdan Sorbye, Marianne Ellen Pavel, Matthias M Weber, Irvin Modlin, Thomas M Gress. Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine?Gut 2021; 70(9): 1768 doi: 10.1136/gutjnl-2020-321300
50
G. García Rayado, M.A. Simón Marco. Tumores del intestino delgado. Pólipos intestinales. Poliposis familiares. Síndrome carcinoide. Linfomas. Sarcomas intestinalesMedicine - Programa de Formación Médica Continuada Acreditado 2016; 12(4): 189 doi: 10.1016/j.med.2016.02.012
51
Eva Lesén, Åse Björstad, Ingela Björholt, Tom Marlow, Entela Bollano, Marion Feuilly, Florence Marteau, Staffan Welin, Anna-Karin Elf, Viktor Johanson. Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish studyScandinavian Journal of Gastroenterology 2018; 53(12): 1509 doi: 10.1080/00365521.2018.1531653
52
Norberto Perico, Piero Ruggenenti, Annalisa Perna, Anna Caroli, Matias Trillini, Sandro Sironi, Antonio Pisani, Eleonora Riccio, Massimo Imbriaco, Mauro Dugo, Giovanni Morana, Antonio Granata, Michele Figuera, Flavio Gaspari, Fabiola Carrara, Nadia Rubis, Alessandro Villa, Sara Gamba, Silvia Prandini, Monica Cortinovis, Andrea Remuzzi, Giuseppe Remuzzi, Maarten W. Taal. Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trialPLOS Medicine 2019; 16(4): e1002777 doi: 10.1371/journal.pmed.1002777
53
Jaume Capdevila, Enrique Grande, Rocío García-Carbonero, Marc Simó, Mª Isabel del Olmo-García, Paula Jiménez-Fonseca, Alberto Carmona-Bayonas, Virginia Pubul. Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand TherapyThe Oncologist 2022; 27(4): e328 doi: 10.1093/oncolo/oyab041
54
Kavisha R. Ulapane, Brian M. Kopec, Mario E. G. Moral, Teruna J. Siahaan. Peptides and Peptide-based Biomaterials and their Biomedical ApplicationsAdvances in Experimental Medicine and Biology 2017; 1030: 167 doi: 10.1007/978-3-319-66095-0_8
55
Luohai Chen, Jie Chen. Perspective of neo-adjuvant/conversion and adjuvant therapy for pancreatic neuroendocrine tumorsJournal of Pancreatology 2019; 2(3): 91 doi: 10.1097/JP9.0000000000000023
56
Tetsuhide Ito, Lingaku Lee, Robert T. Jensen. Carcinoid-syndromeCurrent Opinion in Endocrinology & Diabetes and Obesity 2018; 25(1): 22 doi: 10.1097/MED.0000000000000376